A great place to work, according to Science

AbbottAbbott is among the best science-based companies to work for in the world. For the 13th consecutive year, the journal Science recognized Abbott on its Top Employers list, evaluated on 23 characteristics including financial strength, easy adaptation to change and a having a research-driven environment.

"Abbott is unique in that we've been adding to our reservoir of scientific knowledge for 128 years," said John Frels, Ph.D., chair of Abbott's Scientific Governing Board, which oversees the company's senior scientific career track. "We strive to bring in the best and brightest scientists and engineers to work on some of the biggest problems in healthcare today. This helps us to create new, breakthrough innovations that change people's lives."

The clarity of Abbott's mission to help people live better, fuller lives through the power of health creates an environment that fosters growth and development as a scientist, Frels said - and ultimately leads to our next great innovations.

"We place great importance on the patient - the person that our products are ultimately designed to help." Frels said. "And that appeals to the hearts and the minds of our scientists - they know that what they're doing is making a difference in people's lives."

Scientists at Abbott are given opportunities to advance science, technology, medicine and nutrition to help people live fuller and more complete lives. The company recognizes this commitment through a number of internal recognition efforts, including chairman's awards, president's awards, and patent and inventor awards. The company honors its most distinguished scientists and engineers with induction into the prestigious Volwiler Society, named for the late Ernest H. Volwiler, Ph.D., an internationally recognized scientist and former Abbott president and chairman of the board.

In addition to being honored for workplace leadership by Science, FORTUNE magazine has named Abbott as one of "America's Most Admired Companies" every year since the list's inception in 1983. Working Mother and DiversityInc magazines have also ranked Abbott as a top employer, and the National Association for Female Executives again named Abbott among the Top 50 Companies for Executive Women in 2016.

About the 2016 Science Survey
Nearly 6,000 scientists from around the world (56 percent North America; 28 percent Europe; and 12 percent Asia/Pacific Rim) voted on the companies they considered the best, average and worst employers. Here's a complete list of the rankings, which are also available in the Oct. 28, 2016, print edition of Science.

About Abbott
At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life.

Today, 74,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...

Researchers identify chemical compound that inhibi…

An organic chemical compound shows effective antiviral activity against Ebola virus and several other viruses, according to a study led by Georgia State University. The r...

When drugs are wrong, skipped or make you sick: Th…

Rising drug prices have gotten a lot of attention lately, but the actual cost of prescription medications is more than just the dollars and cents on the bill. Researchers...